Clinical Trial Results: Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 pilot study investigating cabazitaxel and paclitaxel in HER2-negative metastatic breast cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust | Conditions: HER2 Negative Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-07-21